• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Crypto-Related Stocks Are Trading Lower: Here Are 34 Stocks Moving Premarket

    8/19/22 7:24:10 AM ET
    $AGLE
    $AVYA
    $AXDX
    $BBBY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $AGLE alert in real time by email

    Gainers

    • Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) shares rose 88.3% to $0.9507 in pre-market trading after the company announced a marketing authorization application for pegzilarginase for the treatment of Arginase 1 deficiency has been submitted to and successfully validated by the European Medicines Agency.
    • Summit Therapeutics Inc. (NASDAQ:SMMT) shares rose 60% to $1.60 in pre-market trading. Summit Therapeutics CFO Ankur Dhingra recently acquired a total of 36,215 shares at an average price of $0.97.
    • GigaCloud Technology Inc (NASDAQ:GCT) rose 25.5% to $19.70 in pre-market trading after jumping 28% on Thursday. The company priced its IPO at $12.25 per share.
    • Genius Group Limited (NYSE:GNS) rose 22.7% to $10.45 in pre-market trading after jumping 33% on Thursday. Genius Group, last month, appointed Erez Simha as CFO.
    • Bill.com Holdings, Inc. (NYSE:BILL) shares rose 20.1% to $179.49 in pre-market trading after the company announced better-than-expected Q4 results and issued sales guidance above estimates.
    • System1, Inc. (NYSE:SST) rose 19.4% to $13.74 in pre-market trading after gaining 9% on Thursday.
    • Marpai, Inc. (NASDAQ:MRAI) rose 18.8% to $0.95 in pre-market trading. Marpai Director Yaron Eitan recently acquired a total of 31,000 shares at an average price of $0.79.
    • GreenBox POS (NASDAQ:GBOX) rose 18.3% to $1.68 in pre-market trading after dropping 21% on Thursday. Greenbox recently reported better-than-expected Q2 sales.
    • TDH Holdings, Inc. (NASDAQ:PETZ) rose 15.1% to $3.43 in pre-market trading after declining 30% on Thursday.
    • Weber Inc. (NYSE:WEBR) shares rose 13.4% to $11.36 in pre-market trading after gaining 27% on Thursday. Weber recently reported better-than-expected Q3 sales results.
    • Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) rose 12.7% to $1.15 in pre-market trading. Mind Medicine shares jumped 36% on Thursday amid attention towards the stock on social media.
    • Avaya Holdings Corp. (NYSE:AVYA) rose 12.1% to $0.73 in pre-market trading. Avaya recently received New York Stock Exchange notice regarding late form 10-Q filing.
    • Quotient Limited (NASDAQ:QTNT) rose 10.8% to $0.2298 in pre-market trading. Quotient recently said Q1 EPS results were lower year over year and worse-than-expected Q1 sales results.
    • Endo International plc(NASDAQ:ENDP) rose 7.8% to $0.4375 in pre-market trading after jumping 43% on Thursday. Endo International recently filed for bankruptcy after reaching a $6 billion deal with some of its creditors as the company sought to settle opioid-related lawsuits.
    • Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) rose 7.7% to $0.2386 in pre-market trading. Corbus Pharmaceuticals recently posted a Q2 loss of $0.11 per share.


    Don’t forget to check out our premarket coverage here .

    Losers

    • Capstone Green Energy Corporation (NASDAQ:CGRN) shares fell 42.4% to $2.27 in pre-market trading after the company announced the launch of an underwritten public offering.
    • Bed Bath & Beyond Inc. (NASDAQ:BBBY) fell 41.1% to $10.92 in pre-market trading after a new SEC filing confirmed that GameStop chair Ryan Cohen sold his stake in the home furnishings retailer.
    • Lizhi Inc. (NASDAQ:LIZI) shares fell 17.5% to $1.45 in pre-market trading after reporting Q2 results.
    • Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) fell 15.2% to $0.24 in pre-market trading. Clarus Therapeutics posted a Q2 loss of $0.24 per share.
    • Vinco Ventures, Inc. (NASDAQ:BBIG) fell 14.5% to $1.24 in pre-market trading.
    • Accelerate Diagnostics, Inc. (NASDAQ:AXDX) fell 14.5% to $2.13 in pre-market trading as the company priced an underwritten public offering of 17,500,000 shares at $2.00 per share.
    • Plus Therapeutics, Inc. (NASDAQ:PSTV) fell 14.3% to $0.7250 in pre-market trading. Plus Therapeutics shares gained 54% on Thursday after the company announced it was awarded $17.6 million Product Development Research grant by the Cancer Prevention and Research Institute of Texas to fund radiotherapeutic, Rhenium-186 NanoLiposome
    • Bright Minds Biosciences Inc. (NASDAQ:DRUG) fell 12.9% to $1.89 in pre-market trading. Shares of Bright Minds Biosciences jumped 136% on Thursday amid an increase in retail investor interest.
    • VistaGen Therapeutics, Inc. (NASDAQ:VTGN) fell 12.6% to $0.1950 in pre-market trading. VistaGen Therapeutics reports in Form4 filing that CEO Shawn K. Singh bought 600,000 shares at average price of $0.17 per share.
    • StoneCo Ltd. (NASDAQ:STNE) fell 12.2% to $10.24 in pre-market trading after the company reported Q2 results and said Marcelo Baldin, Chief Financial Officer, is departing from the company.
    • Magic Empire Global Limited (NASDAQ:MEGL) shares fell 12% to $12.00 in pre-market trading on volatility following the company's IPO earlier this month.
    • Blue Water Vaccines, Inc. (NASDAQ:BWV) fell 12% to $3.77 in pre-market trading after dipping 44% on Thursday.
    • Neptune Wellness Solutions Inc. (NASDAQ:NEPT) fell 11.4% to $1.79 in pre-market trading. Neptune Wellness shares jumped around 50% on Thursday after the company announced sales have outperformed Walmart's expectations.
    • Marathon Digital Holdings, Inc (NASDAQ:MARA) fell 11.2% to $13.84 in pre-market trading amid a decline in Bitcoin and Ethereum prices.. Marathon Digital recently posted a Q2 loss of $1.75 per share.
    • Riot Blockchain, Inc. (NASDAQ:RIOT) fell 10.4% to $7.39 in pre-market trading amid a decline in Bitcoin and Ethereum prices.
    • Hut 8 Mining Corp. (NASDAQ:HUT) fell 10% to $2.42 in pre-market trading after declining 10% on Thursday. The company launched at-the-market equity program of up to $200 million.
    • GameStop Corp. (NYSE:GME) fell 9.8% to $34.20 in pre-market trading after dropping more than 6% on Thursday.
    • Nova LifeStyle, Inc. (NASDAQ:NVFY) shares fell 9% to $0.82 in pre-market trading after dropping 18% on Thursday.
    • MicroStrategy Incorporated (NASDAQ:MSTR) fell 8.4% to $297.20 in pre-market trading amid a decline in Bitcoin and Ethereum prices.
    Get the next $AGLE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGLE
    $AVYA
    $AXDX
    $BBBY

    CompanyDatePrice TargetRatingAnalyst
    MARA Holdings Inc.
    $MARA
    2/9/2026$8.00Underweight
    Morgan Stanley
    StoneCo Ltd.
    $STNE
    2/9/2026$22.00Buy
    BTIG Research
    BILL Holdings Inc.
    $BILL
    2/6/2026$50.00 → $46.00Market Perform
    BMO Capital Markets
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    Hut 8 Corp.
    $HUT
    2/2/2026$80.00Buy
    H.C. Wainwright
    Strategy Inc
    $MSTR
    1/27/2026$213.00Overweight
    Cantor Fitzgerald
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    More analyst ratings

    $AGLE
    $AVYA
    $AXDX
    $BBBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on StoneCo with a new price target

    BTIG Research initiated coverage of StoneCo with a rating of Buy and set a new price target of $22.00

    2/9/26 7:01:42 AM ET
    $STNE
    EDP Services
    Technology

    Morgan Stanley initiated coverage on MARA Holdings Inc. with a new price target

    Morgan Stanley initiated coverage of MARA Holdings Inc. with a rating of Underweight and set a new price target of $8.00

    2/9/26 7:01:42 AM ET
    $MARA
    EDP Services
    Technology

    BMO Capital Markets reiterated coverage on Bill.com with a new price target

    BMO Capital Markets reiterated coverage of Bill.com with a rating of Market Perform and set a new price target of $46.00 from $50.00 previously

    2/6/26 6:48:02 AM ET
    $BILL
    EDP Services
    Technology

    $AGLE
    $AVYA
    $AXDX
    $BBBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

    PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

    2/12/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BILL to Participate in Upcoming Investor Conferences

    BILL (NYSE:BILL), the intelligent finance platform trusted by half a million businesses to manage, move and maximize their money, announced today its participation in the following conferences: Susquehanna Technology Conference in New York on Thursday, February 26, 2026 Morgan Stanley Technology, Media & Telecom Conference in San Francisco on Tuesday, March 3, 2026 Management will participate in a fireside chat at 10:45 a.m. PST Wolfe FinTech Forum in New York on Tuesday, March 10, 2026 A live webcast of the Morgan Stanley event will be accessible at https://investor.bill.com. Webcast replays can be accessed from BILL's Investor Relations website for approximately thirty da

    2/12/26 4:05:00 PM ET
    $BILL
    EDP Services
    Technology

    Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

    NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026. 36th Annual Oppenheimer Healthcare Life Sciences Conference Format: Virtual presentation and one-on-one investor meetings Date: February 25, 2026 Presentation Time: 3:20pm Eastern TimeWebcast Link: Click Here About CorbusCorbus Pharmaceuticals Holdings, Inc. is a clinical stage oncolog

    2/12/26 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $AVYA
    $AXDX
    $BBBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mealer-Burke Vicki was granted 82,759 shares, increasing direct ownership by 142% to 140,862 units (SEC Form 4)

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    2/13/26 9:05:35 PM ET
    $MARA
    EDP Services
    Technology

    Director Leupp Jay P was granted 82,759 shares, increasing direct ownership by 46% to 261,618 units (SEC Form 4)

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    2/13/26 9:03:23 PM ET
    $MARA
    EDP Services
    Technology

    Director Humpton Barbara was granted 82,759 shares, increasing direct ownership by 154% to 136,339 units (SEC Form 4)

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    2/13/26 9:02:13 PM ET
    $MARA
    EDP Services
    Technology

    $AGLE
    $AVYA
    $AXDX
    $BBBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cheng Lawrence bought $114,368 worth of shares (5,000 units at $22.87) (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/26/26 9:06:47 AM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    President, CEO and Chairman Cohen Ryan bought $21,359,200 worth of shares (1,000,000 units at $21.36), increasing direct ownership by 3% to 38,347,842 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/22/26 4:02:03 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    Director Attal Alain bought $259,577 worth of shares (12,000 units at $21.63), increasing direct ownership by 2% to 596,464 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/21/26 6:32:09 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    $AGLE
    $AVYA
    $AXDX
    $BBBY
    SEC Filings

    View All

    PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Leadership Update

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    2/13/26 4:09:33 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Marpai, Inc. (0001844392) (Filer)

    2/13/26 4:05:56 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by Bright Minds Biosciences Inc.

    6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

    2/13/26 6:04:46 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $AVYA
    $AXDX
    $BBBY
    Leadership Updates

    Live Leadership Updates

    View All

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Cineverse and GameStop Invite Fans to 'Return to Silent Hill' with Innovative Partnership featuring Mysterious Messages, Exclusive Rewards, In-Store Media & More

    Return to Silent Hill Hits Theaters Nationwide on January 23 – Buy Tickets Now LOS ANGELES and GRAPEVINE, Texas, Jan. 14, 2026 /PRNewswire/ -- Cineverse (NASDAQ:CNVS), a next generation entertainment studio, and GameStop Corp. (NYSE:GME), are pulling out all the stops in anticipation of the January 23 wide theatrical release of Return to Silent Hill (returntosilenthillmovie.com).  The two companies are collaborating on an immersive marketing campaign for the new film, based on the visionary video game, SILENT HILL 2. Since January 7, fans who visit a participating GameStop ca

    1/14/26 3:02:00 PM ET
    $CNVS
    $GME
    Consumer Electronics/Video Chains
    Consumer Discretionary
    Electronics Distribution

    StoneCo Announces New CEO, Reinforcing Continuity and Execution

    George Town, Grand Cayman--(Newsfile Corp. - January 7, 2026) - StoneCo Ltd. (NASDAQ:STNE) ("Stone" or "the Company") announces today that Mr. Pedro Zinner has informed the Board of Directors of his decision to resign from his position as Chief Executive Officer, effective March 2026, for personal reasons.Mr. Zinner assumed the role of CEO three years ago, following his service on the Company's Board, at a critical moment in Stone's trajectory. During his tenure, Stone executed a clear strategic pivot, including the divestment of non-core assets such as Linx, the implementation of broad streamlining initiatives, the establishment of a disciplined capital allocation framework, and meaningful

    1/7/26 7:10:00 AM ET
    $STNE
    EDP Services
    Technology

    $AGLE
    $AVYA
    $AXDX
    $BBBY
    Financials

    Live finance-specific insights

    View All

    Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

    PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

    2/12/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BILL Reports Second Quarter Fiscal Year 2026 Financial Results

    Q2 Core Revenue Increased 17% Year-Over-Year Q2 Total Revenue Increased 14% Year-Over-Year BILL (NYSE:BILL), the intelligent finance platform trusted by half a million businesses to manage, move and maximize their money, today announced financial results for the second fiscal quarter ended December 31, 2025. "We delivered a strong Q2, with a significant beat on revenue and profitability, and continued our track record of rapid innovation," said René Lacerte, BILL CEO and Founder. "With a leading position in a large market, strong brand recognition, and a differentiated platform and distribution ecosystem, we are leveraging our unique assets alongside AI to eliminate unnecessary wor

    2/5/26 4:01:00 PM ET
    $BILL
    EDP Services
    Technology

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    $AGLE
    $AVYA
    $AXDX
    $BBBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care